Found is the least expensive option on this page and, unusually, the low price does not come with a hollowed-out service. Obesity-medicine clinicians, one-to-one behaviour coaching and 503A compounding all sit inside $99 a month, which is a genuinely surprising combination at that figure.
Obesity medicine also brings a habit that matters here: it looks past the scale to the metabolic picture underneath. That earns Found partial marks on being believed and on honest metabolic framing, which is more than most affordable providers manage.
Here is how Found reads against each promise of the Whole-Woman Charter. Each promise is marked none, partial or strong; price is shown but is never part of the rating. GLP-1 medications are not a treatment for endometriosis.
The plan bundles clinician oversight, 503A titration and structured coaching. For a condition you live with rather than resolve, having a named person who checks in is worth more than it usually gets credit for, and Found is the cheapest place here to get it. Dose fit scores strong; lasting care and cost both sit at partial, reflecting a service that publishes its structure honestly.
The coaching frame is behaviour — eating, movement, routine. It is not built to account for a condition where fatigue and pain are unpredictable and where a plan that assumes a steady week may simply not survive a bad one. Care here is not organised around hormonal or gynecologic history, so how well the coaching adapts depends on the individual coach rather than on the model. Worth establishing early.
Put these to Found in writing, and keep the reply.
Found is the best value on this page and the coaching earns that. It rates mid-Charter because the whole apparatus is built around weight and behaviour rather than around a person managing a chronic condition. For many readers that will still be the right trade at $99.
What is above comes from what this provider chooses to publish, and providers revise their terms without saying so — treat it as a starting point and check it yourself. Havelle is editorial, not clinical: none of this is medical advice, and GLP-1 medications are not a treatment for endometriosis.